Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers.
BACKGROUND
Our previous study demonstrated that Helicobacter pylori eradication was less effective in smokers than in non-smokers. Cetraxate is an anti-ulcer drug that increases gastric mucosal blood flow.


OBJECTIVE
To evaluate the effect of cetraxate combined with new triple therapy for the eradication of H. pylori in smokers.


METHODS
This study had a single-centre, double-blind, randomized non-placebo design. A total of 106 consecutive H. pylori-positive smoking patients were randomly allocated to one of two regimens: one group received omeprazole (20 mg), amoxycillin (1500 mg), and clarithromycin (600 mg) for 7 days (OAC, n=55). The other group recieved OAC plus cetraxate (600 mg) for 7 days (OAC + CET, n=51). The success of H. pylori eradication was evaluated by histology and the 13C-urea breath test at 4 weeks after completion of treatment.


RESULTS
By intention-to-treat analysis, the H. pylori eradication rate was 55% in the OAC group and 92% in the OAC + CET group (P<0.01). By per protocol analysis, the H. pylori eradication rate was 58% in the OAC group and 94% in the OAC + CET group (P<0.01).


CONCLUSIONS
Cetraxate combined with new triple therapy increases the eradication of H. pylori in smokers.
Gastrointestinal Unit, First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan.
T
T
Kamada
K
K
Haruma
E
E
Miyoshi
M
M
Mihara
Y
Y
Kitadai
M
M
Yoshihara
K
K
Sumii
G
G
Kajiyama
K
K
Tahara
T
T
Mukai
Y
Y
Kawamura
N
N
Hattori
D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D010406:Penicillins / Q000008:administration & dosage*; D012039:Regional Blood Flow; D012907:Smoking; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010406:Penicillins; C000665:cetraxate; D014148:Tranexamic Acid; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole